Literature DB >> 25091267

Stereotactic body radiotherapy for liver tumors: principles and practical guidelines of the DEGRO Working Group on Stereotactic Radiotherapy.

Florian Sterzing1, Thomas B Brunner, Iris Ernst, Wolfgang W Baus, Burkhard Greve, Klaus Herfarth, Matthias Guckenberger.   

Abstract

PURPOSE: This report of the Working Group on Stereotactic Radiotherapy of the German Society of Radiation Oncology (DEGRO) aims to provide a practical guideline for safe and effective stereotactic body radiotherapy (SBRT) of liver tumors.
METHODS: The literature on the clinical evidence of SBRT for both primary liver tumors and liver metastases was reviewed and analyzed focusing on both physical requirements and special biological characteristics.
RESULTS: Recommendations were developed for patient selection, imaging, planning, treatment delivery, motion management, dose reporting, and follow-up. Radiation dose constraints to critical organs at risk are provided.
CONCLUSION: SBRT is a well-established treatment option for primary and secondary liver tumors associated with low morbidity.

Entities:  

Mesh:

Year:  2014        PMID: 25091267     DOI: 10.1007/s00066-014-0714-1

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  77 in total

1.  Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma.

Authors:  M Sherman; K Burak; J Maroun; P Metrakos; J J Knox; R P Myers; M Guindi; G Porter; J R Kachura; P Rasuli; S Gill; P Ghali; P Chaudhury; J Siddiqui; D Valenti; A Weiss; R Wong
Journal:  Curr Oncol       Date:  2011-10       Impact factor: 3.677

2.  Inter- and intrafraction variability in liver position in non-breath-hold stereotactic body radiotherapy.

Authors:  Robert B Case; Jan-Jakob Sonke; Douglas J Moseley; John Kim; Kristy K Brock; Laura A Dawson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-07-21       Impact factor: 7.038

3.  Stereotactic body radiation therapy in recurrent hepatocellular carcinoma.

Authors:  Wen-Yen Huang; Yee-Min Jen; Meei-Shyuan Lee; Li-Ping Chang; Chang-Ming Chen; Kai-Hsiung Ko; Kuen-Tze Lin; Jang-Chun Lin; Hsing-Lung Chao; Chun-Shu Lin; Yu-Fu Su; Chao-Yueh Fan; Yao-Wen Chang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-02-17       Impact factor: 7.038

4.  Stereotactic radiotherapy of hepatocellular carcinoma: preliminary results.

Authors:  C Louis; S Dewas; X Mirabel; T Lacornerie; A Adenis; F Bonodeau; E Lartigau
Journal:  Technol Cancer Res Treat       Date:  2010-10

5.  Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution.

Authors:  Michael G House; Hiromichi Ito; Mithat Gönen; Yuman Fong; Peter J Allen; Ronald P DeMatteo; Murray F Brennan; Leslie H Blumgart; William R Jarnagin; Michael I D'Angelica
Journal:  J Am Coll Surg       Date:  2010-05       Impact factor: 6.113

6.  Radiobiological investigation of dose-rate effects in intensity-modulated radiation therapy.

Authors:  Florian Sterzing; Marc W Münter; Mattias Schäfer; Peter Haering; Bernhard Rhein; Christoph Thilmann; Jürgen Debus
Journal:  Strahlenther Onkol       Date:  2005-01       Impact factor: 3.621

7.  [Stereotactic irradiation of liver metastases].

Authors:  K K Herfarth; J Debus; F Lohr; M L Bahner; M Wannenmacher
Journal:  Radiologe       Date:  2001-01       Impact factor: 0.635

8.  Image-guided robotic stereotactic radiosurgery for unresectable liver metastases: preliminary results.

Authors:  Giovanni Ambrosino; Francesco Polistina; Giorgio Costantin; Paolo Francescon; Rosabianca Guglielmi; Pierluigi Zanco; Franco Casamassima; Antonio Febbraro; Giorgio Gerunda; Franco Lumachi
Journal:  Anticancer Res       Date:  2009-08       Impact factor: 2.480

9.  Planning 4-dimensional computed tomography (4DCT) cannot adequately represent daily intrafractional motion of abdominal tumors.

Authors:  Jiajia Ge; Lakshmi Santanam; Camille Noel; Parag J Parikh
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-10-23       Impact factor: 7.038

10.  Definition of stereotactic body radiotherapy: principles and practice for the treatment of stage I non-small cell lung cancer.

Authors:  M Guckenberger; N Andratschke; H Alheit; R Holy; C Moustakis; U Nestle; O Sauer
Journal:  Strahlenther Onkol       Date:  2013-09-21       Impact factor: 3.621

View more
  42 in total

1.  Direct dose correlation of MRI morphologic alterations of healthy liver tissue after robotic liver SBRT.

Authors:  Judit Boda-Heggemann; Anika Jahnke; Mark K H Chan; Leila S Ghaderi Ardekani; Peter Hunold; Jost Philipp Schäfer; Stefan Huttenlocher; Stefan Wurster; Dirk Rades; Guido Hildebrandt; Frank Lohr; Jürgen Dunst; Frederik Wenz; Oliver Blanck
Journal:  Strahlenther Onkol       Date:  2018-02-05       Impact factor: 3.621

Review 2.  ICRU report 91 on prescribing, recording, and reporting of stereotactic treatments with small photon beams : Statement from the DEGRO/DGMP working group stereotactic radiotherapy and radiosurgery.

Authors:  Lotte Wilke; Nicolaus Andratschke; Oliver Blanck; Thomas B Brunner; Stephanie E Combs; Anca-Ligia Grosu; Christos Moustakis; Daniela Schmitt; Wolfgang W Baus; Matthias Guckenberger
Journal:  Strahlenther Onkol       Date:  2019-01-16       Impact factor: 3.621

3.  A novel approach to SBRT patient quality assurance using EPID-based real-time transit dosimetry : A step to QA with in vivo EPID dosimetry.

Authors:  Christos Moustakis; Fatemeh Ebrahimi Tazehmahalleh; Khaled Elsayad; Francis Fezeu; Sergiu Scobioala
Journal:  Strahlenther Onkol       Date:  2020-01-10       Impact factor: 3.621

Review 4.  Radiotherapy for Colorectal Cancer: Current Standards and Future Perspectives.

Authors:  Matthias F Häfner; Jürgen Debus
Journal:  Visc Med       Date:  2016-06-16

5.  Radioablation of adrenal gland malignomas with interstitial high-dose-rate brachytherapy : Efficacy and outcome.

Authors:  K Mohnike; K Neumann; P Hass; M Seidensticker; R Seidensticker; M Pech; S Klose; T Streitparth; B Garlipp; C Benckert; J J Wendler; U B Liehr; M Schostak; D Göppner; G Gademann; J Ricke
Journal:  Strahlenther Onkol       Date:  2017-03-24       Impact factor: 3.621

6.  Under-reported dosimetry errors due to interplay effects during VMAT dose delivery in extreme hypofractionated stereotactic radiotherapy.

Authors:  Tobias Gauer; Thilo Sothmann; Oliver Blanck; Cordula Petersen; René Werner
Journal:  Strahlenther Onkol       Date:  2018-02-15       Impact factor: 3.621

7.  Interobserver variability in target volume delineation of hepatocellular carcinoma : An analysis of the working group "Stereotactic Radiotherapy" of the German Society for Radiation Oncology (DEGRO).

Authors:  E Gkika; S Tanadini-Lang; S Kirste; P A Holzner; H P Neeff; H C Rischke; T Reese; F Lohaus; M N Duma; K Dieckmann; R Semrau; M Stockinger; D Imhoff; N Kremers; M F Häfner; N Andratschke; U Nestle; A L Grosu; M Guckenberger; T B Brunner
Journal:  Strahlenther Onkol       Date:  2017-07-10       Impact factor: 3.621

8.  Stereotactic body radiotherapy (SBRT) in recurrent or oligometastatic pancreatic cancer : A toxicity review of simultaneous integrated protection (SIP) versus conventional SBRT.

Authors:  E Gkika; S Adebahr; S Kirste; T Schimek-Jasch; R Wiehle; R Claus; U Wittel; U Nestle; D Baltas; A L Grosu; T B Brunner
Journal:  Strahlenther Onkol       Date:  2017-01-30       Impact factor: 3.621

9.  Simultaneous integrated protection : A new concept for high-precision radiation therapy.

Authors:  Thomas B Brunner; Ursula Nestle; Sonja Adebahr; Eleni Gkika; Rolf Wiehle; Dimos Baltas; Anca-Ligia Grosu
Journal:  Strahlenther Onkol       Date:  2016-10-18       Impact factor: 3.621

10.  Repeated SBRT for in- and out-of-field recurrences in the liver.

Authors:  Eleni Gkika; Iosif Strouthos; Simon Kirste; Sonja Adebahr; Michael Schultheiss; Dominik Bettinger; Ralph Fritsch; Volker Brass; Lars Maruschke; Hannes Philipp Neeff; Sven Arke Lang; Ursula Nestle; Anca-Ligia Grosu; Thomas Baptist Brunner
Journal:  Strahlenther Onkol       Date:  2018-10-23       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.